General Announcement::Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
25-Jun-2021 14:10:40
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules
Announcement Reference
SG210625OTHRQL95
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
25/06/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

Attachments

SGX_PR_25062021.pdf
Total size =661K